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Why is In-hospital Diagnosis of Pulmonary
Tuberculosis Delayed in Southern Taiwan?
Chun-Yu Lin,1,2† Wei-Ru Lin,1,3† Tun-Chieh Chen,1,2 Po-Liang Lu,1,2 Pei-Ming Huang,4
Zhong-Rong Tsai,4 Ming-Shyan Huang,4 Wen-Cheng Tsai,5 Yen-Hsu Chen1,2,6*
Background/Purpose: In-hospital diagnosis delay (IHDD) of pulmonary tuberculosis (TB) has a signifi-
cant impact on nosocomial TB transmission. We investigated the risk factors associated with prolonged
IHDD in Taiwan, a high-resource, mid-incidence area.
Methods: Between January 2005 and August 2006, we retrospectively enrolled 193 consecutive hospital-
ized patients. All of them had culture-proven pulmonary TB and did not receive antitubercular treatment
at admission. IHDD was defined as the interval between admission and initiation of antitubercular
treatment. Patients were grouped according to the median value of IHDD.
Results: The median IHDD was 7 days. Patients with IHDD >7 days were considered the prolonged-delay
group, and those with IHDD≤7 days, the short-delay group. Independent risk factors [with adjusted odd
ratios (95% confidence intervals)] for prolonged IHDD were: negative sputum smear [47.53
(13.20–171.18), p < 0.001]; non-cavitary lesions on chest radiographs [14.90 (3.46–64.14), p < 0.001];
admission to hospital departments other than chest medicine/infectious diseases [6.60 (1.95–22.41),
p = 0.002]; exposure to fluoroquinolones before antitubercular treatment [5.29 (1.13–24.75), p = 0.034];
underlying malignancy [4.59 (1.13–18.67), p = 0.033); and age > 65 years [3.19 (1.01–10.05), p = 0.048].
Death attributed to tuberculosis was associated with positive sputum smear (hazard ratio = 21.85; 95% 
CI = 2.74–174.44; p = 0.004) but not prolonged IHDD (p = 0.325).
Conclusion: To minimize IHDD, clinicians should carefully manage hospitalized patients with risk factors
for prolonged delay, such as those with negative sputum smears, non-cavitary lesions on chest radiographs,
admission to departments other than chest medicine/infectious diseases, exposure to fluoroquinolones
before antitubercular treatment, underlying malignancy, and age > 65 years.
Key Words: delayed diagnosis, fluoroquinolones, malignancy, risk factors, tuberculosis
©2010 Elsevier & Formosan Medical Association
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Divisions of 1Infectious Diseases and 4Chest Medicine, Department of Internal Medicine, 3Department of Infection Control,
Kaohsiung Medical University Hospital, 2Graduate Institute of Medicine, College of Medicine, 6Tropical Medicine Research
Institute, Kaohsiung Medical University, 5Zuoying Armed Forces General Hospital, Kaohsiung, Taiwan.
Received: February 16, 2009
Revised: June 8, 2009
Accepted: July 2, 2009
*Correspondence to: Dr Yen-Hsu Chen, Division of Infectious Diseases, Department of
Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou 1st Road, Kaohsiung
807, Taiwan.
E-mail: d810070@cc.kmu.edu.tw
†Chun-Yu Lin and Wei-Ru Lin contributed equally to this work.
Even in areas that have implemented the elements
of tuberculosis (TB) control, TB from transmission
of Mycobacterium tuberculosis will continue to de-
velop unless patients are diagnosed early.1 Diag-
nosis delay in TB has been defined as the time
from symptom onset to institution of treatment.2
Diagnosis delay is divided into two major compo-
nents: patient delay and healthcare system delay.3
Areas with different TB incidence show different
diagnosis delay patterns. Healthcare system
delay results in greater intra-institutional spread
of TB,4,5 therefore, it is an important issue in
many general hospitals. This is especially true for
in-hospital diagnosis delay (IHDD), that is, delay
from admission to initiation of antitubercular
treatment. To prevent intra-institutional transmis-
sion of TB, prompt diagnosis and isolation of in-
patients with documented or suspected TB are
recommended in the guidelines published by
the United States Centers for Disease Control
and Prevention.6,7
Several reports of nosocomial TB outbreaks
have indicated that rates of nosocomial transmis-
sion are high when the diagnosis of TB in hospital-
ized patients is delayed.8,9 The longer the IHDD,
the greater the possibility of intra-institutional
transmission. Furthermore, several studies have
reported higher incidence rates of TB in health-
care workers (HCWs) than in the general popula-
tion.10,11 Delayed diagnosis of the index patient is
the main cause of patient-to-HCW transmission.12
Therefore, identifying risk factors for prolonged
IHDD of pulmonary TB might not only decrease
nosocomial transmission but also protect HCWs
from TB infection.
In Taiwan, TB incidence and mortality rates 
in 2005 were 72.47 and 4.27 per 100,000 per-
sons, respectively.13 It is unclear which factors
contribute to prolonged IHDD in Taiwan, a high-
resource area with mid-level incidence of TB (i.e.
50–99 new cases per 100,000 population per
year). Therefore, we designed this retrospective
hospital-based study in a medical center in Taiwan
to investigate risk factors for prolonged IHDD.
We also studied the impact of IHDD on patient
outcomes.
Methods
Patients and setting
Between January 2005 and August 2006, we inves-
tigated all consecutive patients aged ≥15 years 
who had a diagnosis of TB in Kaohsiung Medical
University Hospital (KMUH), a 1600-bed tertiary
care comprehensive hospital in Taiwan. At KMUH,
there are > 45,000 admissions every year, and the
overall ratio of TB to total admissions ranges from
112/10,000 to 148/10,000. The ratio is signifi-
cantly higher among chest medicine/infectious
disease departments (850/10,000 to 1184/10,000)
than in other sections (52/10,000 to 57/10,000).
The responsibility for patient diagnosis and
management sat with individual physicians. No
examination was required by hospital policy but
was carried out on the physician’s orders. Active
pulmonary TB was indicated by either of the fol-
lowing: (1) respiratory specimen culture revealing
M. tuberculosis complex; or (2) M. tuberculosis com-
plex isolated from an extra-pulmonary site, and
parenchymal disease indicated by a concurrent
chest radiograph (CXR).4 Additionally, TB is a no-
tifiable disease in Taiwan. Hence, patient inclusion
was confirmed according to the data generated
from the registration system of the Taiwan Centers
for Disease Control. Each CXR was categorized as:
(1) typical of TB; (2) compatible with TB; or (3)
atypical according to the criteria of Tattevin et al.14
In brief, typical CXR of TB meant the presence of
nodular, alveolar, or interstitial infiltrates that pre-
dominantly affected the zones above the clavicles
or upper zones; or the presence of cavitation that
affected the upper zones or the apical segment of
the lower lobe. CXR compatible with TB indicated
enlarged hilar nodes, pneumonic lesions, atelec-
tasis, mass lesions, miliary lesions and pleural
exudates. Atypical CXR meant any other pattern,
including normal CXR.
According to Greenaway et al, newly diagnosed
patients were those not on active antitubercular
treatment at admission and not transferred from
another healthcare facility with a known or pre-
sumptive active TB diagnosis.4 By this definition,
all new and relapsed TB patients were enrolled 
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in our cohort. We did not exclude those who
were admitted for suspicion of TB but who had
not yet been treated with antitubercular drugs 
at admission. Antitubercular treatment consisted
of at least two of the following first-line agents:
isoniazid, rifampicin, ethambutol, pyrazinamide,
and streptomycin. This study was approved by
the local Institutional Review Board.
Data collection
Patients’ medical records provided admission
dates and the number of days that had elapsed be-
fore antitubercular treatment (i.e. IHDD). After
sorting all IHDD data, we used the median delay
as the cutoff value to categorize patients into a
shorter-delay (SD) or a prolonged-delay (PD)
group. Persons with a positive culture who died
before treatment were also defined as patients;2
their IHDD was taken as the time that had elapsed
between admission and death. Patients who re-
ceived steroids within 14 days before admission
were considered to have steroid exposure. Patients
who received fluoroquinolones (FQs: levofloxacin,
moxifloxacin, or ciprofloxacin) for more than 72
hours between 14 days before admission and initi-
ation of antitubercular treatment were considered
to have FQ exposure.15
The chief complaints of patients were cate-
gorized as respiratory symptoms, constitutional
symptoms, or others.15 Delay in CXR meant that
the first radiograph was taken at least 1 day after
admission. Severe hypoalbuminemia was defined
as serum albumin level <3.0 g/dL. All patients
were followed until they completed antitubercular
treatment or died. The reason for death was de-
termined by individual clinicians based on clini-
cal evaluation, and the TB-attributable mortality
was analyzed.
Statistical analysis
All analyses were conducted using SPSS version
13.0 (SPSS Inc., Chicago, IL, USA). Odds ratios
(OR) and 95% confidence interval (CI) were cal-
culated for binomial variables; p values were calcu-
lated using the χ2 test for discrete variables and
Student’s t test for continuous variables. Variables
with p ≤ 0.05 in the univariate analysis were in-
cluded in a logistic regression model for multi-
variate analysis. Multivariate survival analysis was
performed using a Cox regression model. All
tests were two-tailed, and p ≤ 0.05 was considered
significant.
Results
IHDD
Between January 2005 and August 2006, 193 cul-
ture-proven, newly diagnosed, hospitalized pa-
tients with pulmonary TB were enrolled. Their
demographic characteristics are shown in Table 1.
Among the 193 patients, 174 (90.2%) had three
sets or more of sputum specimens for acid-fast
bacillus (AFB) examination and 19 (9.8%) had
two sets or less. These 193 patients accounted for a
total of 4072 days of IHDD burden. The median
Table 1. Demographic characteristics of patients in
study cohort (n = 193)*
Age (yr) 63.47 ± 18.04
Sex, male 131 (67.9)
Diagnostic criteria
Positive culture of M. tuberculosis 193 (100)
complex
from respiratory specimens 190 (98.4)
from an extra-pulmonary site 3 (1.6)
Concomitant extra-pulmonary TB† 28 (14.5)
Pleural 15 (7.8)
Miliary 6 (3.1)
Osteoarticular 5 (2.6)
Lymphatic 2 (1.0)
Peritoneal 2 (1.0)
Meningeal 1 (0.5)
Other 1 (0.5)
Underlying malignancy 37 (19.2)
Lung neoplasm 12 (6.2)
Primary 9 (4.7)
Metastatic 3 (1.6)
Other solid organ malignancy 23 (11.9)
without lung involvement
Hematological malignancy 2 (1.0)
*Data are presented as mean± standard deviation or n (%); †4 pa-
tients had double sites involved with tuberculosis. TB=Tuberculosis.
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IHDD was 7 days (duration, 0–162 days; inter-
quartile range, 3–30 days) and the mean IHDD
was 21.1 days. Patients were then classified into
two groups according to their individual IHDD
(Figure). Patients with IHDD ≤ 7 days were as-
signed to the SD group (n = 100), whereas those
with IHDD >7 days were assigned to the PD group
(n = 93).
Of the total 4072 days of IHDD burden, the SD
group accounted for 301 days (7.4%) only, while
the PD group accounted for 3771 days (92.6%).
Univariate analysis of risk factors revealed that
IHDD was longer for patients who were > 65 years
of age, admitted to hospital departments other
than chest medicine/infectious diseases, had un-
derlying malignancy, had been exposed to steroids
or FQs, or had atypical CXRs (Table 2). In contrast,
patients who presented with respiratory symp-
toms as the chief initial complaint, fever > 38.0°C,
weight loss, a history of alcohol abuse, positive
sputum smears, serum albumin<3 g/dL, and CXRs
that showed cavitary lesions, had shorter IHDDs.
Multivariate logistic regression analysis showed
independent risk factors for prolonged IHDD to
be: age >65 years, admission to departments other
than chest medicine or infectious diseases, under-
lying malignancy, exposure to FQs before antitu-
bercular treatment, negative sputum smears, and
absence of cavitary lesions on CXRs (Table 2).
Among 37 patients with underlying malig-
nancy, 12 had primary or metastatic lung neo-
plasms and 25 did not. The mean IHDD of
patients with lung neoplasms was 31.3 days,
whereas the mean IHDD of those without lung
neoplasms was only 19.1 days (p = 0.096).
For every hospitalized patient, once a clinician
initiates the process of specifically diagnosing pul-
monary TB, through sputum AFB examination and
TB culture, for example, diagnosis is not only the
responsibility of the individual clinician, but also
of the hospital, including the laboratory and in-
fection control department. If we further divided
IHDD into two subsets defined as suspicion delay
(i.e. doctor’s delay) and treatment delay (i.e. diag-
nostic process delay),16 we found that suspicion
delay in all 193 patients was 2.5 days (median, 0
days) and treatment delay was 18.6 days (median,
5 days). We also found that suspicion and treat-
ment delay were significantly longer in the PD
than in the SD group (suspicion delay: 4.89 days
vs. 0.27 days, p <0.001; treatment delay: 35.66 days
vs. 2.74 days, p < 0.001).
Outcomes
The median follow-up period was 9 months
(range, 0–22). Ten (5.2%) patients with positive
TB culture results died before treatment, and all of
them were thought to have died from other med-
ical causes. Twenty-one patients died from TB di-
rectly (overall TB-attributable mortality rate was
10.9%). Among the 21 deaths attributable to TB,
13 occurred in the SD group and eight in the PD
group. Patients with positive sputum smears had a
significantly greater relative risk for TB-attributable
mortality (hazard ratio=21.85, p=0.004; Table 3).
However, FQ exposure had no significant effect on
TB-attributable mortality (p = 0.737).
Discussion
Delay in diagnosing TB is an important worldwide
problem. It seriously threatens public health be-
cause it is associated with greater transmission of
infection to contacts,17 and nosocomial spread.
Previous studies that have investigated the causes
of IHDD rarely have taken into account labora-
tory data, except for sputum examination results.
Therefore, we conducted a retrospective study to
investigate the risk factors associated with pro-
longed IHDD in Taiwan, and took account of
0
5
10
15
20
25
30
35
In-hospital diagnosis delay (d)
Pa
ti
en
t 
nu
m
b
er
 (
%
)
0–
3
4–
7
8–
11
12
–1
5
16
–1
9
20
–2
3
24
–2
7
≥ 2
8
Figure. Distribution of in-hospital diagnosis delay for the
study cohort.
Factors delaying TB diagnosis in hospital
J Formos Med Assoc | 2010 • Vol 109 • No 4 273
Table 2. Univariate and multivariate analysis of risk factors for prolonged in-hospital diagnosis delay of pulmonary
tuberculosis
Variable
Prolonged delay Shorter delay Odds ratio Adjusted odds ratio
(n = 93) (n = 100) (95% CI) (95% CI)*
Demographics characteristics
Sex, male 60 (64.5) 71 (71.0) 0.74 (0.39–1.42) –
Age > 65 yr 57 (61.3) 46 (46.0) 1.86 (1.05–3.30)† 3.19 (1.01–10.05)†
Section, non-chest medicine/ 53 (57.0) 20 (20.0) 5.30 (2.80–10.04)† 6.60 (1.95–22.41)†
infectious diseases
Chief complaint
Respiratory symptoms 34 (36.6) 57 (57.0) 0.44 (0.24–0.78)† 0.50 (0.16–1.61)
Constitutional symptoms 26 (28.0) 35 (35.0) 0.72 (0.39–1.33) –
Other symptoms/signs
Cough 67 (72.0) 78 (78.0) 0.73 (0.38–1.40) –
Sputum production 55 (59.1) 58 (58.0) 1.05 (0.59–1.86) –
Hemoptysis 5 (5.4) 7 (7.0) 0.76 (0.23–2.47) –
Dyspnea 21 (22.6) 33 (33.0) 0.59 (0.31–1.12) –
Fever > 38°C 34 (36.6) 53 (53.0) 0.51 (0.29–0.91)† 0.53 (0.18–1.54)
Weight loss 6 (6.5) 27 (27.0) 0.19 (0.07–0.48)† 0.24 (0.04–1.66)
Underlying disease
Concurrent extra-pulmonary TB 14 (15.1) 14 (14.0) 1.09 (0.49–2.43) –
Chronic obstructive pulmonary 15 (16.1) 11 (11.0) 1.56 (0.68–3.59) –
disease
Previous TB history 12 (12.9) 5 (5.0) 2.82 (0.95–8.33) –
Cerebrovascular disease 8 (8.6) 5 (5.0) 1.79 (0.56–5.68) –
HIV/AIDS 1 (1.1) 3 (3.0) 0.35 (0.04–3.44) –
Malignancy 25 (26.9) 12 (12.0) 2.70 (1.26–5.75)† 4.59 (1.13–18.67)†
Congestive heart failure 17 (18.3) 10 (10.0) 2.01 (0.87–4.66) –
Diabetes mellitus 27 (29.0) 32 (32.0) 0.87 (0.47–1.61) –
ESRD with hemodialysis 4 (4.3) 2 (2.0) 2.20 (0.39–12.32) –
Liver cirrhosis 8 (8.6) 3 (3.0) 3.04 (0.78–11.84) –
Personal habits
Cigarette smoking 42 (45.2) 57 (57.0) 0.62 (0.35–1.10) –
Alcohol abuse history 19 (20.4) 33 (33.0) 0.52 (0.27–1.00)† 0.76 (0.23–2.52)
Medication exposure
Steroids 9 (9.7) 2 (2.0) 5.25 (1.10–24.98)† 10.72 (0.24–477.50)
Fluoroquinolones 25 (26.9) 5 (5.0) 6.99 (2.55–19.17)† 5.29 (1.13–24.75)†
Microbiological status of sputum
Less than 3 sets of sputum smear 7 (7.5) 12 (12.0) 0.60 (0.22–1.59) –
Smear negative results 68 (73.1) 13 (13.0) 18.20 (8.67–38.21)† 47.5 (13.20–171.18)†
Other laboratory data at admission
Leukocytosis 47 (50.5) 39 (39.0) 1.60 (0.90–2.83) –
Serum albumin < 3 g/dL‡ 24 (25.8) 45 (45.0) 0.43 (0.23–0.78)† 0.40 (0.14–1.17)
Chest radiographs
Delay in taking CXR 6 (6.5) 5 (5.0) 1.31 (0.39–4.45) –
Concurrent pulmonary edema 8 (8.6) 4 (4.0) 2.26 (0.66–7.77) –
Without cavitary lesion on CXR 89 (95.7) 60 (60.0) 14.83 (5.04–43.62)† 14.90 (3.46–64.14)†
Atypical presentation 14 (15.1) 2 (2.0) 8.68 (1.92–39.35)† 6.37 (0.70–57.97)
*Missing data in serum albumin were replaced by the mean value for statistics; †p ≤ 0.05; ‡data unavailable for 33 (17.1%) patients 
(15 in the prolonged delay group and 18 in the shorter delay group). CI = Confidence interval; HIV = human immunodeficiency virus;
AIDS = acquired immunodeficiency syndrome; ESRD = end-stage renal disease; CXR = chest X-ray.
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Table 3. Multivariate risk factors for tuberculosis-attributable death among patients with pulmonary
tuberculosis
Variable Hazard ratio 95% CI p*
In-hospital diagnostic delay > 7 d 0.42 0.07–2.38 0.325
Demographic characteristics
Sex, male 1.14 0.20–6.55 0.886
Age > 65 yr 1.63 0.40–6.62 0.497
Section, non-chest medicine/ 1.56 0.39–6.14 0.528
infectious disease departments
Microbiological status of sputum
Smear-positive results 21.85 2.74–174.44 0.004†
Underlying disease
Concurrent extra-pulmonary TB 3.15 0.59–16.96 0.182
Chronic obstructive pulmonary disease 1.19 0.29–4.87 0.813
Previous TB history 1.42 0.21–9.89 0.721
Cerebrovascular disease 1.40 0.13–14.83 0.779
HIV/AIDS‡ – – –
Malignancy 0.62 0.13–3.03 0.558
Congestive heart failure 1.84 0.41–8.24 0.428
Diabetes mellitus 0.78 0.22–2.75 0.699
ESRD with hemodialysis 6.95 0.40–120.13 0.182
Liver cirrhosis 2.19 0.20–24.48 0.524
Personal habits
Cigarette smoking 2.18 0.44–10.81 0.339
Alcohol consumption 1.45 0.38–5.47 0.584
Symptoms/signs
Cough 0.40 0.08–1.99 0.260
Sputum production 1.43 0.36–5.77 0.612
Hemoptysis 6.80 0.84–54.98 0.072
Dyspnea 2.06 0.55–7.75 0.285
Fever > 38°C 1.26 0.41–3.92 0.688
Weight loss 1.06 0.26–4.28 0.940
Cavitary lesion on CXR 0.92 0.23–3.71 0.905
Laboratory data at admission
Serum albumin < 3 g/dL 1.19 0.38–3.70 0.770
Chest radiographs
Concurrent pulmonary edema 1.81 0.28–11.76 0.534
Concurrent pleural effusion 1.32 0.43–4.05 0.632
Cavitary lesion on CXR 0.92 0.23–3.71 0.905
Atypical presentation 0.75 0.06–9.81 0.824
Drug exposure
Steroids 2.75 0.37–20.47 0.322
Fluoroquinolones 1.36 0.23–7.95 0.737
*Cox regression test; †p < 0.05; ‡no patients died directly from tuberculosis. CI = Confidence interval; IHDD = in-hospital diagnosis
delay; TB = tuberculosis; COPD = chronic obstructive pulmonary disease; HIV = human immunodeficiency virus; AIDS = acquired 
immunodeficiency syndrome; ESRD = end-stage renal disease; CXR = chest x-ray.
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clinical data as well as laboratory data and co-
morbidity. Moreover, to identify the effect of 
FQ exposure on mortality rate, we conducted a
person–time survival analysis.
The median IHDD was 7 days and all patients
were classified into the SD group (IHDD ≤ 7 days)
or PD group (IHDD > 7 days). Suspicion delay
and treatment delay were significantly longer in
the PD than in the SD group. This suggested that
there were some factors that caused clinicians to
delay in raising suspicion, which prolonged the
in-hospital diagnostic process.
Similar to previous studies,18,19 we found that
elderly patients had longer IHDD. This may be ex-
plained by the greater frequency of other con-
comitant medical conditions, such as underlying
malignancy, congestive heart failure, and pul-
monary edema, which render differential diag-
nosis more difficult.2 Typical symptoms of
pulmonary TB, such as weight loss,20 cough, and
fever could help early diagnosis of TB and decrease
IHDD.19 However, elderly patients might not pres-
ent such typical symptoms, might not be able to
expectorate sputum spontaneously, and/or could
present with atypical clinical manifestations of
TB, thereby resulting in delayed diagnosis.21 Thus
an increased awareness of TB prevalence and a
high level of suspicion in elderly patients might
help clinicians lower IHDD.16,21
According to our study, sputum smear results
had a significant impact on IHDD. In agreement
with other studies,22,23 our findings indicated that
patients with smear-positive results had signifi-
cantly shorter IHDD compared with those with
negative results. Furthermore, CXRs might help
clinicians make more precise differential diag-
noses, especially concerning cavitary lesions. Scott
et al also demonstrated that CXRs are of great
value in identifying TB patients, especially those
consistent with cavities, or with apical or nodular
infiltrates.24 In contrast, we observed a trend that
patients with lung malignancy had longer IHDD.
Underlying malignancy might interfere with CXR
interpretation and lead to misdiagnosis or delayed
diagnosis of pulmonary TB.2,25 Although diagnosis
of pulmonary TB based only on CXR findings is 
associated with a greater possibility of changing
diagnosis thereafter,25 we still recommend a more
widespread use of CXRs in daily practice to reduce
IHDD.26 One further factor that we must empha-
size is that 8.3% of all patients presented with
atypical CXRs in their first evaluation. Therefore,
not only CXRs, but also modest clinical evaluation
and laboratory examination are very important.
We also found that IHDD was longer as the
number of TB admissions decreased.4 This might
also explain the difference in IHDD between the
various hospital departments (chest medicine/in-
fectious diseases vs. other departments). It could be
explained partially by the “practice makes perfect”
hypothesis.27 Therefore, clinicians who work in de-
partments with low TB hospitalization rates and
who manage fewer TB patients should be educated
regarding the potential risks of TB, and consulta-
tion with the chest medicine or infectious dis-
eases departments should be strengthened.
As mentioned in several previous studies, em-
pirical administration of FQs delays TB diagnosis
and treatment.15,28 Our study also showed that
exposure to FQs is an independent risk factor for
prolonged IHDD. Therefore, clinicians must be
more careful when prescribing FQs to treat pa-
tients with respiratory symptoms (such as pneu-
monia) caused by unknown pathogens. FQs have
excellent in vitro activity against M. tuberculosis28
and can influence sputum mycobacterial culture
results.15 Therefore, clinicians should obtain ade-
quate respiratory specimens before prescribing
FQs. Although the effect of short-term FQ admin-
istration on the emergence of M. tuberculosis resist-
ance is equivocal,15,29 we still recommend prudent
administration of FQs.
In contrast to a study conducted in the United
Kingdom,30 prolonged IHDD itself was not a main
contributing factor to TB-attributable mortality in
our study. This finding is in agreement with that
of Rao et al,31 who found that there is no asso-
ciation between diagnosis delay and mortality 
in the United States. Franzetti et al also reported
that a delay in initiation of antitubercular treat-
ment does not seem to be a determining factor
in survival time.32 However, other studies have
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shown that a long delay between onset of symp-
toms and initiation of effective antitubercular
treatment (i.e. patient delay plus healthcare system
delay) increases TB mortality.33,34 Earlier diagno-
sis and treatment might reduce deaths, particu-
larly among elderly patients.35
In our cohort, the TB-attributable mortality
rate (10.9%) was higher than the 5.9% rate in
Taiwan.13 It might be explained by two facts: (1)
all patients in this study were hospitalized, mean-
ing that they might have had more serious pul-
monary TB and underlying diseases than those
managed in outpatient departments; and (2) the
study site, KMUH, is a tertiary care hospital that
might receive patients with severe symptoms. In
our study, there was only one factor that con-
tributed to TB-attributable mortality; namely,
being smear-positive for AFB. This could be ex-
plained by the fact that an AFB-positive sputum
smear is a sign of high bacterial burden, which
increases the likelihood of causing death. As
noted by Greenaway et al,4 outcomes are signifi-
cantly worse among smear-positive patients. In
addition, we found that exposure to FQs was not
associated with TB-attributable mortality. The true
effect of FQs on outcomes should be evaluated
carefully in another study.
In our retrospective study, there were some
limitations. First, recording of symptoms such 
as night sweats might have been missed as we
could not record all symptoms of pulmonary TB.
Second, we could not clarify why clinicians ini-
tially started treatment for pulmonary TB on a
patient-by-patient basis.
In conclusion, even experienced clinicians
should be on high alert for pulmonary TB and per-
form adequate examinations as soon as possible3
for hospitalized patients who have suggestive
symptoms in Taiwan, especially those aged >65
years or those receiving FQs. Careful review of un-
derlying malignancy and detailed CXR interpre-
tation might help clinicians decrease IHDD.
Furthermore, continuing medical education for
clinicians who work in hospital departments with
low TB admission rates is needed to strengthen
awareness of TB.
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